Logo

Genmab Reports Results of Darzalex (daratumumab) in P-III COLUMBA Study for Patients with R/R Multiple Myeloma

Share this

Genmab Reports Results of Darzalex (daratumumab) in P-III COLUMBA Study for Patients with R/R Multiple Myeloma

Shots:

  • The P-III COLUMBA (NCT03277105) study involves assessing of Darzalex (SC) + recombinant human hyaluronidase PH20 (2000 U/mL) vs Darzalex (IV) in 522 patients with r/r multiple myeloma
  • The P-III COLUMBA study results: ORR (41.1% vs 37.1%); geometric mean of Maximum Trough concentration (Ctrough) (499 mg/mL vs 463 mg/mL); no new safety signals
  • Darzalex (daratumumab) is IgG1k mAb- with broad spectrum cytotoxic activity targeting CD38 and has received two BT designation from FDA as monothx & combination therapy. In Aug-2012 Janssen Biotech collaborated with Genmab to develop and commercialise daratumumab

Ref: Genmab | Image: Pharma News

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions